PT  - JOURNAL ARTICLE
AU  - Bendor-Samuel, Owen M
AU  - Wishlade, Tabitha
AU  - Willis, Louise
AU  - Aley, Parvinder
AU  - Choi, Edward
AU  - Craik, Rachel
AU  - Mujadidi, Yama
AU  - Mounce, Ginny
AU  - Roseman, Fenella
AU  - De La Horra Gozalo, Arancha
AU  - Bland, James
AU  - Taj, Nazia
AU  - Smith, Ian
AU  - Ziegler, Anette-Gabriele
AU  - Bonifacio, Ezio
AU  - Todd, John A.
AU  - Servais, Laurent
AU  - Snape, Matthew D
AU  - Vatish, Manu
AU  - ,
TI  - Successful incorporation of a genetic risk prediction research platform into routine newborn screening
AID  - 10.1101/2021.02.26.21252305
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.26.21252305
4099  - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252305.short
4100  - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252305.full
AB  - An increasing number of diseases can be offered treatments that are transformative if administered in a timely manner. However, many of these diseases are currently not included in the newborn screening programs because they lack sensitive and specific metabolic biomarkers and their detection relies on genetic methods. Type 1 diabetes (T1D) constitutes a potential example of such disease.Between April 2018 and November 2020, over 15500 babies were enrolled into ‘INGR1D’ (Investigating Genetic Risk for T1D), a research study to identify newborns with an increased genetic risk of T1D. This project, performed as part of a T1D primary prevention study (the Primary Oral Insulin Trial, POInT), has helped to pioneer the integration of genetic screening into the NHS Newborn Blood Spot Screening Programme (NBSSP) for consenting mothers, without affecting the screening pathway. The use of prospective consent to perform personalised genetic testing on samples obtained through the routine NBSSP represents a novel mechanism for clinical genetic research in the UK and provides a model for further population based genetic studies in the newborn.This project builds on the UK’s role as a world leader in genomic medicine, e.g. through its inception and completion of the 100 000 Genomes Project, and its subsequent ambition to map 5 million further genomes over the next 5 years.Our aim is therefore to describe the methodology used by INGR1D as a way to demonstrate how a successful research and clinical trial tool can be integrated into a national screening programme, with the potential for the tool to be developed to incorporate multiple diseases with genetic markers without altering the screening pathway.Competing Interest StatementMDS works on behalf of the University of Oxford as an investigator on clinical research projects funded or supported by vaccine manufacturers including GSK, Pfizer, Janssen, Novavax, MedImmune, MCM vaccines and Astra Zeneca. He receives no personal payment for this work. JAT is a member of a GSK Human Genetics Advisory Board Funding StatementLeona M. and Harry B. Helmsley Charitable Trust, Grant/Award Numbers: 2018PG-T1D022, 2018PG-T1D026. The work was supported by the Juvenile Diabetes Research Fund: 5-SRA-2015-130-A-N, 4-SRA-2017-473-A-N; the Wellcome: 107212/Z/15/Z, 203141/Z/16/Z.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Screening Programme Research Advisory Committee, and the Hampshire A Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData mentioned in the manuscript is held either by the Oxford Vaccine Group, University of Oxford, or the Nuffield Department of Women's and Reproductive Health, University of Oxford